Truvada (TDF) Kidney & Bone Damage Lawsuit
HIV medications containing tenofovir disoproxil fumarate (TDF) — including Truvada, Viread, Atripla, Complera, and Stribild — have caused severe kidney damage and bone density loss. Lawsuits allege Gilead Sciences delayed a safer alternative.
Defendant: Gilead Sciences, Inc. | Cases consolidated in California state court. JCCP 5043.
Key Facts
Who Qualifies
Individuals who took Truvada, Viread, Atripla, Complera, or Stribild (TDF-based HIV medications) and suffered kidney damage or bone-related injuries.
Related Injuries
- Chronic kidney disease
- Kidney failure
- Fanconi syndrome
- Osteoporosis
- Bone fractures
- Bone density loss
- Renal tubular dysfunction
- Lactic acidosis
Settlement Status
No global settlement has been reached. Thousands of cases are pending in California state court.
Learn More About This Lawsuit
Truvada (TDF) Lawsuit Overview
Everything you need to know about the Truvada lawsuit — TDF kidney damage, bone loss, and Gilead Sciences litigation.
Do I Qualify for the Truvada Lawsuit?
Find out if you qualify for the Truvada (TDF) lawsuit. Eligibility for kidney damage and bone loss claims.
Truvada Lawsuit Settlement Amounts — April 2026 Update
Latest information on Truvada (TDF) lawsuit settlements, expected payouts, and case value projections.
Truvada Lawsuit FAQ
Frequently asked questions about the Truvada (TDF) lawsuit — eligibility, kidney damage, bone loss, and Gilead litigation.
You May Also Qualify For
You may also qualify for these active lawsuits:
ATTORNEY ADVERTISING. This website may be considered attorney advertising in some jurisdictions.
This website is for informational purposes only and does not constitute legal advice. No attorney-client relationship is formed by using this site or submitting a contact form. Prior results do not guarantee a similar outcome.
Free Case Review
Find out if you may qualify for compensation. No cost, no obligation.
ATTORNEY ADVERTISING. This website may be considered attorney advertising in some jurisdictions.